# Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany: Phase 2 study closed enrollment, 381 enrolled (Systemic Lupus Erythematosus)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) |
| NCT ID | NCT05540327 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Systemic Lupus Erythematosus |
| Intervention types | drug |
| Target enrollment | 381 |
| Site countries | United States, Argentina, Australia, Brazil, Bulgaria, Chile, China, Colombia, Greece, Israel, Japan, Mauritius |
| Posted | 2022-09-14 |
| Planned start | 2022-09-16 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-15 |
| Last update posted | 2026-10-15 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.
- 381 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05540327). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.